Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, ...

San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what ...

Corporation announced that the Company closed the subscription period of its previously announced rights offering at 5:00 PM ...

CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results. The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M, ...

Cytosorbents ( (CTSO) ) has shared an update. CytoSorbents Corporation successfully closed an oversubscribed rights offering, raising $6.25 million in aggregate gross proceeds, which satisfies a debt ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.71, a high ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The ...

13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood ...

Fourth quarter product revenue is estimated to be in the range of $9M to $9.2M, representing 22% to 25% growth versus $7.35 million in the ...

Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL ...

23, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement press release.